<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Topical Nitric Oxide Donating Prostaglandin Analogues - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVjVzOBOOIBGYUkEU1xKgAAABI","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues","wgTitle":"Topical Nitric Oxide Donating Prostaglandin Analogues","wgCurRevisionId":87696,"wgRevisionId":87696,"wgArticleId":18947,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Glaucoma"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues","wgRelevantArticleId":18947,"wgIsProbablyEditable":!1,
"wgRelevantPageIsProbablyEditable":!1,"wgRestrictionEdit":[],"wgRestrictionMove":[],"sdgDownArrowImage":"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,"wgVisualEditor":{"pageLanguageCode":"en"
,"pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"srfFilteredConfig":null,"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eyeWiki",
"ext.eyeWiki.slideshow","sentry.init","ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Glaucoma is the most frequent cause of irreversible blindness worldwide.&amp;#91;1&amp;#93; It was estimated to affect 76 million people aged 40-80 years in 2020, with a projection of 111.8 million by 2040.&amp;#91;2&amp;#93; Elevated intraocular pressure (IOP) is the primary risk factor for glaucoma. Numerous IOP-lowering medications have been developed, including topical prostaglandin analogues (PGAs), which are currently the first-line medical therapy for most types of glaucoma."/>
<meta name="date" content="2022-12-24"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Topical Nitric Oxide Donating Prostaglandin Analogues" href="/w/index.php?title=Special:ExportRDF/Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues rootpage-Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Topical+Nitric+Oxide+Donating+Prostaglandin+Analogues" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Topical+Nitric+Oxide+Donating+Prostaglandin+Analogues" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpzyvbj13"></button>
					<div class="collapse navbar-collapse hbpzyvbj13" id="hbpzyvbj13">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk" class="new"><a href="/w/index.php?title=Talk:Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues&amp;action=edit&amp;redlink=1" rel="discussion" title="Discussion about the content page (page does not exist) [t]" accesskey="t" class="new ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Topical Nitric Oxide Donating Prostaglandin Analogues</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Abdelrahman.Elhusseiny" title="User:Abdelrahman.Elhusseiny">Abdelrahman M. Elhusseiny, MD, MSc</a>,&#8201;<a href="/User:Ahmed.Sallam" title="User:Ahmed.Sallam">Ahmed Sallam, MD PhD FRCOphth</a>,&#8201;<a href="/User:Noah.Brown" title="User:Noah.Brown">Noah Brown</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#160;<a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#160;<a href="/User:Abdelrahman.Elhusseiny" title="User:Abdelrahman.Elhusseiny">Abdelrahman M. Elhusseiny, MD, MSc</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Up to Date</b>
</div>
</div>&#160;by <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a> on December 25, 2022.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table></div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Introduction"><span class="tocnumber">1</span> <span class="toctext">Introduction</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Latanoprostene_Bunod"><span class="tocnumber">2</span> <span class="toctext">Latanoprostene Bunod</span></a></li>
<li class="toclevel-1 tocsection-3"><a href="#NCX_470"><span class="tocnumber">3</span> <span class="toctext">NCX 470</span></a></li>
<li class="toclevel-1 tocsection-4"><a href="#Conclusion"><span class="tocnumber">4</span> <span class="toctext">Conclusion</span></a></li>
<li class="toclevel-1 tocsection-5"><a href="#References"><span class="tocnumber">5</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Introduction">Introduction</span></h1>
<p>	Glaucoma is the most frequent cause of irreversible blindness worldwide.<sup id="cite_ref-1" class="reference"><a href="#cite_note-1">&#91;1&#93;</a></sup> It was estimated to affect 76 million people aged 40-80 years in 2020, with a projection of 111.8 million by 2040.<sup id="cite_ref-2" class="reference"><a href="#cite_note-2">&#91;2&#93;</a></sup> Elevated intraocular pressure (IOP) is the primary risk factor for glaucoma. Numerous IOP-lowering medications have been developed, including topical prostaglandin analogues (PGAs), which are currently the first-line medical therapy for most types of glaucoma. 
</p><p>	Recently, two nitric oxide (NO)-donating PGAs, latanoprostene bunod (LBN) 0.024% (Vyzulta®) and NCX 470 (Nicox SA), have been introduced. These drugs have dual mechanisms that have been proposed to improve the IOP-lowering capabilities of currently prescribed glaucoma medications. 
</p><p>Once exposed to esterases within the eye, LBN and NCX 470 are cleaved into their respective metabolites; a prostaglandin F2-alpha (PGF2α) agonist and a NO-donating moiety.<sup id="cite_ref-:1_3-0" class="reference"><a href="#cite_note-:1-3">&#91;3&#93;</a></sup><sup id="cite_ref-:0_4-0" class="reference"><a href="#cite_note-:0-4">&#91;4&#93;</a></sup> PGF2α agonists increase uveoscleral outflow via matrix-metalloproteinase-mediated remodeling of the ciliary muscle, while NO induces vasodilation and smooth muscle relaxation, increasing trabecular outflow and decreasing IOP. 
</p>
<h1><span class="mw-headline" id="Latanoprostene_Bunod">Latanoprostene Bunod</span></h1>
<p>LBN is a novel NO-donating PGA metabolized in the eye into latanoprost acid, a PGF2α agonist, and butanediol mononitrate, a NO-donating moiety.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5">&#91;5&#93;</a></sup> Once LBN is metabolized, latanoprost acid binds to its receptor and increases uveoscleral outflow. This is accomplished by metalloproteinases that remodel the ciliary muscle's extracellular matrix.<sup id="cite_ref-:8_6-0" class="reference"><a href="#cite_note-:8-6">&#91;6&#93;</a></sup> In addition, butanediol mononitrate can donate NO within the eye resulting in increased aqueous humor outflow via relaxation of the trabecular meshwork and Schlemm's canal.<sup id="cite_ref-7" class="reference"><a href="#cite_note-7">&#91;7&#93;</a></sup>
</p><p>	To assess safety and efficacy, a series of clinical studies compared varying concentrations of LBN to two currently prescribed glaucoma medications, latanoprost 0.005% and timolol 0.5%. 
</p><p>The JUPITER study suggested that LBN 0.024% once daily was safe, well-tolerated, and resulted in no serious adverse effects for up to one year. The JUPITER study also demonstrated that LBN 0.024% resulted in a mean IOP reduction of 4.2 mm Hg (22%) at 4 weeks and 5.3 mm Hg (25%) at 52 weeks compared to baseline levels (p&lt;0.001).<sup id="cite_ref-:2_8-0" class="reference"><a href="#cite_note-:2-8">&#91;8&#93;</a></sup> The VOYAGER study compared LBN at varying concentrations to latanoprost 0.005%. LBN 0.024% and 0.040% provided a significantly greater mean diurnal IOP reduction compared to latanoprost 0.005%, with reductions of 9.00 (p=0.005), 8.93 (p=0.009), and 7.77 mm Hg, respectively.<sup id="cite_ref-9" class="reference"><a href="#cite_note-9">&#91;9&#93;</a></sup> The CONSTELLATION study indicated that treatment with LBN 0.024% once daily significantly reduced the mean nocturnal IOP by 2.5 ± 3.1 mm Hg (p=0.002) compared to timolol 0.5%, which had a reduction of 2.3 ± 3.0 mm Hg (p=0.004).<sup id="cite_ref-:3_10-0" class="reference"><a href="#cite_note-:3-10">&#91;10&#93;</a></sup> 
</p><p>Two further studies, the APOLLO and LUNAR studies, were pooled and analyzed. Results showed that LBN 0.024% once daily resulted in more significant IOP-lowering effects than timolol 0.5% twice daily over 12 months.<sup id="cite_ref-:4_11-0" class="reference"><a href="#cite_note-:4-11">&#91;11&#93;</a></sup> <sup id="cite_ref-:5_12-0" class="reference"><a href="#cite_note-:5-12">&#91;12&#93;</a></sup>Over 12 months, LBN 0.024% of treated eyes had a least-squares (LS) mean of mean IOP range of 17.8 to 18.7 mm Hg (p&lt;0.001). In contrast, timolol 0.5% had an LS mean IOP range of 19.0 to 19.7 mm Hg. The APOLLO and LUNAR pooled analysis also showed that LBN safety was comparable to PGA treatment alone.<sup id="cite_ref-:6_13-0" class="reference"><a href="#cite_note-:6-13">&#91;13&#93;</a></sup> 
</p><p>A recent retrospective study conducted  by Radell and colleagues demonstrated the safety and efficacy of LBN 0.024% over two years. Results of this study indicated that LBN 0.024% was generally well-tolerated and decreased IOP by 2.1 ± 3.5 mm Hg (p&lt;0.0001) at the first follow-up (38.7 ± 36.5 days) and 2.5 ± 3.3 mm Hg (p&lt;0.0001) at the last follow-up (235.9 ± 160.8 days).<sup id="cite_ref-:7_14-0" class="reference"><a href="#cite_note-:7-14">&#91;14&#93;</a></sup>
</p><p>Table 1 summarizes the major clinical studies evaluating the efficacy and safety of LBN.
</p>
<table class="wikitable">
<caption>
</caption>
<tbody><tr>
<td colspan="7"><b>Table 1: Summary of major clinical studies on LBN for treatment of primary open angle glaucoma (POAG) and ocular hypertension (OHT)</b>
</td></tr>
<tr>
<td><b>Study</b>
</td>
<td><b>Study Design</b>
</td>
<td><b>Number of Study Eyes (Patients)</b>
</td>
<td><b>Percentage of Patients on IOP-lowering Medication Within 30 Days of Enrollment</b>
</td>
<td><b>Mean Age of Study Population</b>
</td>
<td><b>Follow-up Period</b>
</td>
<td><b>Results</b>
</td></tr>
<tr>
<td><i><b>JUPITER</b></i>
<p><i>Kawase and colleagues.</i><sup id="cite_ref-:2_8-1" class="reference"><a href="#cite_note-:2-8">&#91;8&#93;</a></sup>
</p>
</td>
<td>Single-arm, open-label
</td>
<td>130 (130)
</td>
<td>90.0%
</td>
<td>62.5 ± 18.9 years
</td>
<td>12 months
</td>
<td><b>Mean reduction of IOP:</b>
<p>At 4 weeks: 4.3 mm Hg (22%)
</p><p>At 52 weeks: 5.3 mm Hg (25%)
</p><p><b>Most common adverse effects:</b>
</p><p>Conjunctival hyperemia: 17.7%
</p><p>Growth of eyelashes: 16.2%
</p><p>Eye irritation: 11.5%
</p><p>Eye pain: 10.0%
</p><p>Increased iris pigmentation: 10.0%
</p>
</td></tr>
<tr>
<td><i><b>VOYAGER</b></i>
<p><i>Weinreb and colleagues.</i><sup id="cite_ref-:1_3-1" class="reference"><a href="#cite_note-:1-3">&#91;3&#93;</a></sup>
</p>
</td>
<td>Phase II, randomized, investigator-masked, parallel-group, dose-ranging
</td>
<td>413 (413)
</td>
<td>56.4%
</td>
<td>61.0 ± 11.44 years
</td>
<td>28 days
</td>
<td><b>Mean reduction of diurnal IOP (p-Value):</b>
<p>LBN 0.006%: 7.81 mm Hg (0.913)
</p><p>LBN 0.012%: 8.26 mm Hg (0.258)
</p><p>LBN 0.024%: 9.00 mm Hg (0.005)
</p><p>LBN 0.040%: 8.93 mm Hg (0.009)
</p><p>Latanoprost 0.005%: 7.77 mm Hg
</p>
</td></tr>
<tr>
<td><i><b>CONSTELLATION</b></i>
<p><i>Liu and colleagues.</i><sup id="cite_ref-:3_10-1" class="reference"><a href="#cite_note-:3-10">&#91;10&#93;</a></sup>
</p>
</td>
<td>Randomized crossover
</td>
<td>25 (25)
</td>
<td>24%
</td>
<td>60.3 ± 10.6 years
</td>
<td>28 days
</td>
<td><b>Mean reduction of nocturnal IOP (p-Value):</b>
<p>LBN 0.024%: 2.5 ± 3.1 mm Hg (0.002)
</p><p>Timolol 0.5%: 2.3 ± 3.0 mm Hg (0.004)
</p>
</td></tr>
<tr>
<td><i><b>APOLLO</b></i>
<p><i>Weinreb and colleagues.</i><sup id="cite_ref-:4_11-1" class="reference"><a href="#cite_note-:4-11">&#91;11&#93;</a></sup>
</p>
</td>
<td>Phase III, randomized, multicenter, double-masked, parallel-group
</td>
<td>420 (420)
</td>
<td>71.9%
</td>
<td>64.2 ± 10.6 years
</td>
<td>3 months
</td>
<td><b>LS mean of mean IOP (p-Value):</b>
<p>LBN 0.024% range: 17.8 - 18.7 mm Hg (≤0.002 at all timepoints)
</p><p>Timolol 0.5% range: 19.1 - 19.8 mm Hg
</p>
</td></tr>
<tr>
<td><i><b>LUNAR</b></i>
<p><i>Medeiros and colleagues.</i><sup id="cite_ref-:5_12-1" class="reference"><a href="#cite_note-:5-12">&#91;12&#93;</a></sup>
</p>
</td>
<td>Phase III, randomized, multicenter, double-masked, parallel-group
</td>
<td>387 (387)
</td>
<td>72%
</td>
<td>64.7 ± 9.75 years
</td>
<td>3 months
</td>
<td><b>LS mean of the mean IOP (p-Value):</b>
<p>LBN 0.024% range: 17.7 – 19.2 mm Hg (≤0.25 at all time points except for the 8 AM measurement at week 2 – 0.216)
</p><p>Timolol 0.5% range: 18.8 – 19.6 mm Hg
</p>
</td></tr>
<tr>
<td><i><b>APOLLO and LUNAR Pooled Analysis</b></i>
<p><i>Weinreb and colleagues.</i><sup id="cite_ref-:6_13-1" class="reference"><a href="#cite_note-:6-13">&#91;13&#93;</a></sup>
</p>
</td>
<td>Phase III, randomized, multicenter, double-masked, parallel-group, noninferiority
</td>
<td>840 (840)
</td>
<td>72%
</td>
<td>64.5 ± 10.2 years
</td>
<td>12 months
</td>
<td><b>LS mean of mean IOP (P-Value):</b>
<p>LBN 0.024% range: 17.8 - 18.9 mm Hg (&lt;0.001 at all timepoints)
</p><p>Timolol 0.5% range: 19.0 - 19.7 mm Hg
</p>
</td></tr>
<tr>
<td><i><b>Two Year Experience with Latanoprostene Bunod in Clinical Practice</b></i>
<p><i>Radell and colleagues.</i><sup id="cite_ref-:7_14-1" class="reference"><a href="#cite_note-:7-14">&#91;14&#93;</a></sup>
</p>
</td>
<td>Retrospective review
</td>
<td>102 (56)
</td>
<td>100%
</td>
<td>68.8 ± 12.4 years
</td>
<td>24 months
</td>
<td><b>Mean IOP change (p-Value):</b>
<p>Visit 1 vs. visit 2 (before LBN prescription): +1.3 ± 4.0 mm Hg (0.002)
</p><p>Visit 2 vs. visit 3 (prescription until first follow-up on LBN): -2.1 ± 3.5 mm Hg (&lt;0.0001)
</p><p>Visit 3 vs. visit 4 (prescription until last follow-up on LBN): -2.5 ± 3.3 mm Hg (&lt;0.0001)
</p><p>Visit 3 vs. visit 4 (first follow-up on LBN until last follow-up on LBN): -0.3 ± 3.1 mm Hg (0.28)
</p>
</td></tr></tbody></table>
<h1><span class="mw-headline" id="NCX_470">NCX 470</span></h1>
<p>NCX 470, like LBN, is a NO-donating PGA with the chemical name hexanoic acid.<sup id="cite_ref-:8_6-1" class="reference"><a href="#cite_note-:8-6">&#91;6&#93;</a></sup> NCX 470 is metabolized into prostamide bimatoprost, which is then further metabolized into bimatoprost acid and 6-(nitrooxy)-hexanoic acid.<sup id="cite_ref-:0_4-1" class="reference"><a href="#cite_note-:0-4">&#91;4&#93;</a></sup> Bimatoprost acid is a PGF2α agonist, while 6-(nitrooxy)-hexanoic acid is a NO-donating moiety.<sup id="cite_ref-:0_4-2" class="reference"><a href="#cite_note-:0-4">&#91;4&#93;</a></sup> 
</p><p>The Dolomites trial is the only clinical trial that investigated NCX 470. This study compared NCX 470 at varying concentrations (0.021%, 0.042%, and 0.065%) to latanoprost 0.005% at 8:00 AM, 10:00 AM, and 4:00 PM each week for 4 weeks. NCX 470 treatment decreased the mean diurnal IOP at week 4 for all three concentrations that were non-inferior to latanoprost 0.005%. After 4 weeks, NCX 470 0.021%, 0.042%, and 0.065% decreased diurnal IOP by 7.83, 8.24, and 8.67 mmHg, respectively (p&lt;0.0001). Comparatively, latanoprost 0.005% resulted in a diurnal IOP reduction of 7.43 mm Hg after four weeks. NCX 470 0.042% and NCX 470 0.065% displayed a statistically significantly greater reduction in mean diurnal IOP compared to latanoprost 0.005% (p=0.0281 and 0.0009, respectively).<sup id="cite_ref-:0_4-3" class="reference"><a href="#cite_note-:0-4">&#91;4&#93;</a></sup>
</p><p>	In terms of safety, a greater percentage of patients in the NCX 470 0.021% (30.6%), 0.042% (48.1%), and 0.065% (46.7%) treatment groups experienced at least 1 ocular treatment-emergent adverse event (TEAE) compared to the latanoprost 0.005% treatment group (19.6%). The most common TEAE was conjunctival hyperemia, experienced by 10.8%, 22.2%, and 16.8% of patients in the NCX 470 0.021%, 0.042%, and 0.065% treatment groups, respectively. The second most common TEAE was instillation site pain at 7.2%, 9.3%, and 11.2% for the NCX 470 0.021%, 0.042%, and 0.065% treatment groups, respectively. Four total ocular TEAEs in three patients resulted in study withdrawal due to conjunctival hyperemia and instillation eye pain or conjunctival hyperemia and dry eye. Despite these reported adverse events, NCX 470 was well-tolerated at all three dosages.<sup id="cite_ref-:0_4-4" class="reference"><a href="#cite_note-:0-4">&#91;4&#93;</a></sup>
</p><p>NCX 470 treatment decreased the mean diurnal IOP at week 4 for all three concentrations that were non-inferior to latanoprost 0.005%. After 4 weeks, NCX 470 0.021%, 0.042%, and 0.065% decreased diurnal IOP by 7.83, 8.24, and 8.67 mmHg, respectively (p&lt;0.0001). Comparatively, latanoprost 0.005% resulted in a diurnal IOP reduction of 7.43 mm Hg after four weeks. NCX 470 0.042% and NCX 470 0.065% displayed a statistically significantly greater reduction in mean diurnal IOP compared to latanoprost 0.005% (p=0.0281 and 0.0009, respectively).<sup id="cite_ref-:0_4-5" class="reference"><a href="#cite_note-:0-4">&#91;4&#93;</a></sup>
</p><p>	A phase III clinical trial named Mont Blanc is currently underway and has recently closed screening for additional patients. Nicox SA is expected to release results from this study as early as November 2022 and will include the safety and efficacy of a higher dosage, NCX 470 0.1%.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15">&#91;15&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Conclusion">Conclusion</span></h1>
<p>	Current PGAs such as latanoprost and bimatoprost are effective at lowering IOP and treating glaucoma. However, novel drugs like LBN and NCX 470 may have superior IOP reduction capability due to their ability to donate NO.
</p>
<h1><span class="mw-headline" id="References">References</span></h1>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-1"><span class="mw-cite-backlink"><a href="#cite_ref-1">↑</a></span> <span class="reference-text">Jonas JB, Aung T, Bourne RR, et al. Glaucoma. Lancet. 2017;309:2183–2193.</span>
</li>
<li id="cite_note-2"><span class="mw-cite-backlink"><a href="#cite_ref-2">↑</a></span> <span class="reference-text">Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A Systematic review and meta analysis. Ophthalmology 2014;121:2081-90</span>
</li>
<li id="cite_note-:1-3"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:1_3-0">3.0</a></sup> <sup><a href="#cite_ref-:1_3-1">3.1</a></sup></span> <span class="reference-text">Weinreb, R. N., Ong, T., Scassellati Sforzolini, B., Vittitow, J. L., Singh, K., &amp; Kaufman, P. L. (2015). A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: The VOYAGER study. British Journal of Ophthalmology, 99(6), 738</span>
</li>
<li id="cite_note-:0-4"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:0_4-0">4.0</a></sup> <sup><a href="#cite_ref-:0_4-1">4.1</a></sup> <sup><a href="#cite_ref-:0_4-2">4.2</a></sup> <sup><a href="#cite_ref-:0_4-3">4.3</a></sup> <sup><a href="#cite_ref-:0_4-4">4.4</a></sup> <sup><a href="#cite_ref-:0_4-5">4.5</a></sup></span> <span class="reference-text">Walters TR, Kothe AC, Boyer JL, et al. A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study. <i>J Glaucoma</i>. 2022;31(6):382-391.</span>
</li>
<li id="cite_note-5"><span class="mw-cite-backlink"><a href="#cite_ref-5">↑</a></span> <span class="reference-text">Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. <i>Eye (Lond)</i>. 2020;34(1):72-88.</span>
</li>
<li id="cite_note-:8-6"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:8_6-0">6.0</a></sup> <sup><a href="#cite_ref-:8_6-1">6.1</a></sup></span> <span class="reference-text">Mohan N, Chakrabarti A, Nazm N, Mehta R, Edward DP. Newer advances in medical management of glaucoma. <i>Indian J Ophthalmol</i>. 2022;70(6):1920-1930.</span>
</li>
<li id="cite_note-7"><span class="mw-cite-backlink"><a href="#cite_ref-7">↑</a></span> <span class="reference-text">Wiederholt M, Sturm A, Lepple-Wienhues A. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. <i>Invest Ophthalmol Vis Sci</i>. 1994;35(5):2515-2520.</span>
</li>
<li id="cite_note-:2-8"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:2_8-0">8.0</a></sup> <sup><a href="#cite_ref-:2_8-1">8.1</a></sup></span> <span class="reference-text">Kawase K, Vittitow JL, Weinreb RN, Araie M; JUPITER Study Group. Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study. <i>Adv Ther</i>. 2016;33(9):1612-1627.</span>
</li>
<li id="cite_note-9"><span class="mw-cite-backlink"><a href="#cite_ref-9">↑</a></span> <span class="reference-text">Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. <i>Br J Ophthalmol</i>. 2015;99(6):738-745.</span>
</li>
<li id="cite_note-:3-10"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:3_10-0">10.0</a></sup> <sup><a href="#cite_ref-:3_10-1">10.1</a></sup></span> <span class="reference-text">Liu JHK, Slight JR, Vittitow JL, Scassellati Sforzolini B, Weinreb RN. Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours. <i>Am J Ophthalmol</i>. 2016;169:249-257. </span>
</li>
<li id="cite_note-:4-11"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:4_11-0">11.0</a></sup> <sup><a href="#cite_ref-:4_11-1">11.1</a></sup></span> <span class="reference-text">Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study. <i>Ophthalmology</i>. 2016;123(5):965-973.</span>
</li>
<li id="cite_note-:5-12"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:5_12-0">12.0</a></sup> <sup><a href="#cite_ref-:5_12-1">12.1</a></sup></span> <span class="reference-text">Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study. <i>Am J Ophthalmol</i>. 2016;168:250-259.</span>
</li>
<li id="cite_note-:6-13"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:6_13-0">13.0</a></sup> <sup><a href="#cite_ref-:6_13-1">13.1</a></sup></span> <span class="reference-text">Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. <i>J Glaucoma</i>. 2018;27(1):7-15.</span>
</li>
<li id="cite_note-:7-14"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:7_14-0">14.0</a></sup> <sup><a href="#cite_ref-:7_14-1">14.1</a></sup></span> <span class="reference-text">Radell JE, Sharma HK, Auyeung KL, et al. Two-Year Experience With Latanoprostene Bunod in Clinical Practice. <i>J Glaucoma</i>. 2021;30(9):776-780.</span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><a href="#cite_ref-15">↑</a></span> <span class="reference-text">Nicox SA. (2022 June 3) Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022 [Press release]. https://www.nicox.com/wp-content/uploads/EN_-NCX-470-Mont-Blanc-LPFV-PR_20220603_FA.pdf</span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230306035153
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0.032 seconds
CPU time usage: 0.145 seconds
Real time usage: 1.145 seconds
Preprocessor visited node count: 612/1000000
Post‐expand include size: 5879/2097152 bytes
Template argument size: 1286/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 0/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 8656/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  552.456      1 Template:Article
100.00%  552.456      1 -total
 88.10%  486.708      4 Template:Infobox_section
 19.23%  106.247      5 Template:UserLookup
  7.69%   42.497      1 Template:Review_expired
  0.26%    1.411      1 Template:Get_active_contest
  0.17%    0.924      1 Template:Infobox_end
  0.17%    0.913      1 Template:Infobox_begin
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues&amp;oldid=87696">https://eyewiki.org/w/index.php?title=Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues&amp;oldid=87696</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpzyvbkpb">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues&amp;oldid=87696" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Topical_Nitric_Oxide_Donating_Prostaglandin_Analogues&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on December 25, 2022, at 17:04.</div>
					<div>This page has been accessed 2,259 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAFgAAAAfCAMAAABUFvrSAAACJVBMVEXe3t62trbLy8vGxsbAwMDX19e6urqsrKxHcEzQ0NC2tratra2oqKixsbHd3eDFxcXe3t7U1NTa2trX19fQ0NDV1dWNjY2dnZ2UlJSUlJTS0tKUlJSWlpbR0dGenp79/f38/Pz+/v7t7e3v7+/u7u7s7Oz19fX29vb6+vr7+/vz8/Pz8/P4+fnw8PD39/gWTq/09PX6+vktX7b/sg8XT7F6mc/f5OwhVrNvkMthhsfT2+j7rQ/M1eZqjcmFotPs7e9Cb722xuFResK/zOObstnu7/Grvd3M1+mNqNY6aLoaUbEaUbZWfsTk6fE2Zrnp7O8bTq0kWLQuYcpcg8Xh5/Byk83a4eukud1/nM+6yeQkWcGwwuDxnRQyYrigttvI0+gpW7XGyttLdsBni8geVLo0Z9XlkCPb4u+QqtcfVLLo7PNHcr73phFGX6HsmBnpkxg6bNwnXcbX3er19vnr7/SVrdhuhLl+j70vVqY6Xqv0oxJVcbQhV76DjKTz9ffQ2evE0OZAbbzu7/PS1uFufrDnrGgpSZjy8/SQnMFddrKuekXSiCsgTKRaaZHejy9yang3VptNaqspWbnmliy3j2/m6OzT3e7x8fL4+v3p6uwaN2re0cifqLiLiZWYhYGYb0xXYn+5g0xwiMKYpc2BcHZmW2srRXpGWIhecKfilz4+WID2+PyosMywqbGqss1aVnLZq33p1sGklZqrp7dkfr7CpY9yg59Ud6QZAAAAH3RSTlPfBN/f39/f2wDf39vV3/7N2rrEz5D5c8ONuHaPuXXDImoxqwAABO1JREFUSMe1kQdz01gQgBXaBS4w9OtHwMFSdPKTUNxkW+61xN2Je4tLHJNOGukkAUINJTzaUIbO9fr7TpLtS44DZiC5b6Sn3dW+TysJaWz4cv9eZFPZu/+bhkakYR88WqP59u3vjxzdDCT7GpCD4qNH3sEGzOhB5MCR/4PmA8j25uZ33t0A23lxff5hZTIzOrz2Ph8qK936l7i1tT7hk8DAoHNsbeLWKjPdQcZ+qvX9tHMNXca1XBDXHtL6x2Bh0HWtuXUo8oTgC1gVpcdsdpew92PUYtjwzFq+E9mJYfXxx1x5l2/l5Vhy0DW6TuyQCZcR2hnswXJM0h+203471u5WKMIE5mDpspIIO8sZTMZiIbczY6+JCaI+/sJZ38qjP28+nQjkx/mcqGJ26rW3iKg/fYphCL1jNk5WbqXI0nBnu00RJ2j9bNRp6MmFS0SYIXLuUlQ5w22qizHr5MTyy2u/3XxVvHHlwtWVa/xTCQIIlEaMzrgswzA5P9BrAciYASqNoiNdjL8b0GYAHN3AGAEgzPSQc9UtYCeyBQAMO2G9PhhzXfp9qdifSCT6Lj788QQnrvWEuNPI2um0LW0D+m4A6E4AnIZOeq7ksQuJvi6eUXRW+8EWXsxNPhkYGJiSXr7Rd1qtVp9MXHkgIurzAkdFxjrj7cmKbN4K5v8RGxT2sJMTpwBflNHhUJgBdoUylzy3TuwIDBRi0hf9p9VtbW3qk30X7q2Je1IybZq7mLVWFKTSADXPoqi9AzVorda0kKTS6KkRbSgaR1GT1h5CObYiW1GU27yc5z6F9Fn/yTYedeLi9AIA6AbgxGIxAMPZcZeUHH9cFavVfY97FaNA/DbazRZVV89/61at2BTlg1JXiFtrYoBmRyd7p6/UP0XxaSDmy4pt0jmuh8qx6wQ2MmRz18TaJCUWO9xisUVhMMsoZZDiGHLLuXUbso2iatP/1HvhYu3n3bh6Pe/LUjZSj1NUJ8lSlNwahRRlMRjmyFDICikVn8+SacomdbZTVj+0mQSxweS1WqpiHK/Ncubs858f9idOJ/qKS1cv+RbFuIbMmHEvTbO4QeF25CxyD62nSbmJ1MUzRrpiwR0RPBJMpnCGxWVGXBn8TkarNGQHjuPrxOeWY4GY9FmxWHy19Gvv+ayYF6f8oYi7i8U93bjFkYokvbhWEFu8Og2ZxrUe3NMpc3vLhqqYpVV4XbwDQkpgoVwYKOR9N5d+eXB5vJevQA0pD7oVqi4WOj16vX6EYSA08WKvyeOZJw1cQ6rsnXOa/RYoM0Kls0zLuVoHhHAHL8YFXkwVCoE8uXhvMVCY8mW5Ci8eKkcgJ9azOl0UajNDFiUpj5JeloEqTgwd/iCUJP0sFMSejkpO96b4zl1fPuYiyd6Vs4GBmHSsJoYmLy/WeBTlis5rlJYrgjhe1s+XOXGEtHJOMl4VB2EHLauKdyG7JBLIc//uslRKkhOrcGJqyiU9z5UkOpVOwiGXSyQizRAfqlRc7Y5KJFnV6FReiWSV7xAWeQd/SOSq6qY18eVHq4vjlyazEJ73ScmJPVxJVKdF9MFwYpFIEL+ehvDOcSH8YXRsAa4XfwS7kd0tLfw7Sp7fl7xJywbYjTTVotfTb+849lEcb0K+2lMN/5o+tons+Rxp+PrQ8U3n0BcNSGPj4W+bPuX5ZLNo+uxwY+PfoLJHX1KXgyMAAAAASUVORK5CYII=" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0.032},"limitreport":{"cputime":"0.145","walltime":"1.145","ppvisitednodes":{"value":612,"limit":1000000},"postexpandincludesize":{"value":5879,"limit":2097152},"templateargumentsize":{"value":1286,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":0,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":8656,"limit":5000000},"timingprofile":["100.00%  552.456      1 Template:Article","100.00%  552.456      1 -total"," 88.10%  486.708      4 Template:Infobox_section"," 19.23%  106.247      5 Template:UserLookup","  7.69%   42.497      1 Template:Review_expired","  0.26%    1.411      1 Template:Get_active_contest","  0.17%    0.924      1 Template:Infobox_end","  0.17%    0.913      1 Template:Infobox_begin"]},"cachereport":{"timestamp":"20230306035153","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":3125});});</script></body>
</html>